Features

Current Standing and Future Directions of CAR T Therapy for Chronic Lymphocytic Leukemia

By

John Schieszer, MA

CAR T therapy has emerged in recent years as a feasible treatment for patients with chronic lymphocytic leukemia, but there are still many unanswered questions.

Overcoming Challenges in Mechanical Circulatory Support: A Guide for Hematologists

By

Roxanne Nelson, RN, BSN

Mechanical circulatory support (MCS) devices can lead to hemostatic events, making it crucial to include a hematologist on a patient’s MCS management team.

Advances in the Treatment of Hemophilia: Clinical Gene Therapy

By

Caleb Rans, PharmD

Gene therapy with adeno-associated viral viruses could provide an efficacious, safe, and cost-effective treatment option for patients with hemophilia.

Optimizing Transfusion in Patients With Hematologic Malignancies

By

Roxanne Nelson, RN, BSN

Current transfusion recommendations do not adequately inform transfusion in patients with hematologic malignancies, who are increasingly treated as outpatients.

Better Guidelines for Diagnosing Pulmonary Embolism During Pregnancy Needed

By

John Schieszer, MA

Current guidelines to diagnosis pulmonary embolism in pregnant patients offer conflicting recommendations.

Managing Venous Thromboembolism in Transgender Women Receiving Hormone Therapy

By

Lauren Dembeck, PhD

Transgender women receiving hormone replacement therapy may be at an increased risk for thromboembolism, though data and recommendations vary across studies.

The Role of Immune Checkpoint Inhibitors in Treating Hematologic Malignancies

By

Caleb Rans, PharmD

Immune checkpoint inhibitor therapy is associated with improved outcomes but it may also lead to serious adverse effects.

Treating Myelodysplastic Syndrome After Failure of Hypomethylating Agents: Options Remain Limited

By

Roxanne Nelson, RN, BSN

There is a pressing need to develop novel therapeutic strategies for patients with myelodysplastic syndrome who are ineligible for transplantation.

A Novel Screening Program for Severe Combined Immunodeficiency in Newborns

By

Caleb Rans, PharmD

Population-based screening of newborns is crucial to identifying severe combined immunodeficiency before the onset of potentially fatal infection.

The Challenges of Treating Thromboinflammation

By

Roxanne Nelson, RN, BSN

Because dysregulation of coagulation is a key feature of thromboinflammation, coagulation inhibitors may have therapeutic potential.

Assessing Children With Bleeding Symptoms: Coagulation Disorder or Abuse?

By

Lauren Dembeck, PhD

Several factors need to be considered when determining whether a child’s bleeding symptoms are the result of a coagulation disorder, physical abuse, or both.

Clinical Management of Diamond-Blackfan Anemia in Children

By

Caleb Rans, PharmD

Despite deeper understanding of some of the molecular mechanisms underlying Diamond-Blackfan anemia, the search for effective therapies is ongoing.

Case Study: Systemic Lupus Erythematosus With Lupus Nephritis and Thrombotic Microangiopathy

By

Yongen Chang, MD, PhD, and Eric Seronick, DO

A 19-year-old woman presents with complaints of progressive shortness of breath, chest pain, and lower extremity edema over the past month.

Developing Personalized Treatment Strategies for Patients With Multiple Myeloma

By

John Schieszer, MA

Advances in genetic and molecular assessment strategies have led to improved outcomes for patients with multiple myeloma.

Addressing Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy

By

Roxanne Nelson, RN, BSN

There are currently limited data to inform an optimal treatment strategy for cytokine release syndrome, a common complication of CAR T therapy.

Best Imaging Methods for Bone Disease in Multiple Myeloma

By

Roxanne Nelson, RN, BSN

Though imaging provides a powerful tool for diagnosis and treatment of multiple myeloma, choosing the appropriate technique depends on many factors.

Clinical Management of Non-Graft-Versus-Host Disease Ocular Complications Following Hematopoietic Cell Transplantation

By

Caleb Rans, PharmD

Non-GVHD ocular complications can seriously affect patient morbidity and quality of life following hematopoietic cell transplantation.

Updates to Transfusion Strategies for Major Hemorrhage in Trauma

By

Lauren Dembeck, PhD

Changes in clinical management of trauma hemorrhage have significantly reduced mortality rates, but variation in treatment strategies still remains.

Improving the Clinical Diagnosis of Inherited Bleeding Disorders

By

Caleb Rans, PharmD

Many unique challenges surround the diagnosis and treatment of inherited mild bleeding disorders.

Venetoclax, Hypomethylating Agents Are Changing the Treatment Landscape for Acute Myeloid Leukemia

By

John Schieszer, MA

Venetoclax and hypomethylating agents, which both demonstrate single agent activity in acute myeloid leukemia, appear to be more effective when used together.

Can Modifying Microbial Diversity Change Outcomes Following Allogeneic HSCT?

By

Caleb Rans, PharmD

Some studies have found a link between intestinal microbiota composition and development of acute graft-versus-host disease.

Expert Perspective: The Role of Ibrutinib and Venetoclax in Chronic Lymphocytic Leukemia

By

Prithviraj Bose, MD

Hematology Advisor asked Prithviraj Bose, MD, to discuss the latest research on treatment options for CLL presented at the ASH 2018 Annual Meeting.

Updated Clinical Practice Guidelines for Venous Thromboembolism: Pregnant and Pediatric Patients

By

Roxanne Nelson, RN, BSN

In this 3-part series, Hematology Advisor spoke with experts about the revisions to the ASH clinical practice guidelines for venous thromboembolism.

Researchers Report Early Clinical Promise for Macrophage Checkpoint Blockade

By

Bryant Furlow

A doublet immunotherapy regimen incorporating the investigational mAb Hu5F9-G4 shows clinical activity in patients with relapsed/refractory non-Hodgkin lymphoma.

Updated Clinical Practice Guidelines for Venous Thromboembolism: Treatment Strategies

By

Roxanne Nelson, RN, BSN

In this 3-part series, Hematology Advisor spoke with experts about the revisions to the ASH clinical practice guidelines for venous thromboembolism.

CD19 CAR T-Cell Therapies: “Expect an Evolution”

By

Bryant Furlow

“CD19 CAR therapy has paved the way for a new field of medicine based on the genetic instruction of T-cell responses,” according to Dr Michel Sadelin.

Updated Clinical Practice Guidelines for Venous Thromboembolism: Diagnosis and Prophylaxis

By

Roxanne Nelson, RN, BSN

In this 3-part series, Hematology Advisor spoke with experts about the revisions to the ASH clinical practice guidelines for venous thromboembolism.

Clinical Significance of Aspirin and NSAID Antiplatelet Interactions

By

Caleb Rans, PharmD

Concomitant use of aspirin and NSAIDs gives rise to a pharmcodynamic interaction that may interfere with aspirin’s antiplatelet effects.

Clinicians Face Uncertainties in Treating Older Patients With Hodgkin Lymphoma

By

John Schieszer, MA

A lack of research focusing primarily on older patients with Hodgkin lymphoma has led to an unmet need for effective, less toxic treatment in this population.

Advances in Treatment and Prevention of Hemophilia A: Takeaways From the 2018 ASH Annual Meeting

By

Bryant Furlow

Research presented at the 2018 ASH Annual Meeting provided insights into the role of factor VIII as a therapeutic agent for severe hemophilia A.

High Risk of Thrombosis in Myeloproliferative Neoplasms, Underlying Cause Still Unclear

By

Roxanne Nelson, RN, BSN

The prevalence of thrombotic events in patients with myeloproliferative neoplasms can be as high as 39% in some cases.

Controversy Continues Over Relationship Between VTE and Testosterone Therapy

By

John Schieszer, MA

Current clinical data are insufficient to confirm or deny the potential association between risk for VTE and testosterone therapy.

Standard Methodology Needed to Evaluate Pruritus in Cutaneous T Cell Lymphoma

By

Roxanne Nelson, RN, BSN

Though the majority of patients with cutaneous T cell lymphomas experience pruritus, the pathophysiology of the symptom is relatively unclear.

Prognostic Value of Minimal Residual Disease in Indolent Lymphomas

By

Caleb Rans, PharmD

Novel molecular technologies for detecting minimal residual disease may offer prognostic value for patients with indolent lymphomas.

Mixed Evidence on the Role of Vitamin D in Hematopoietic Stem Cell Transplantation

By

Roxanne Nelson, RN, BSN

Recent research suggests that vitamin D deficiency may negatively influence outcomes after hematopoietic stem cell transplantation.

Novel Management Strategies for Myeloma Bone Disease

By

Caleb Rans, PharmD

Therapeutic options for myeloma bone disease include bisphosphonates, immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies.

Managing Atrial Fibrillation in Patients With Beta Thalassemia Major

By

Lauren Dembeck, PhD

Patients with beta thalassemia major may be at higher risk for atrial fibrillation, creating a need for attentive clinical management.

Management of Venous Thrombosis in Unusual Sites

By

John Schieszer, MA

The incidence, pathophysiology, provoking factors, and recommended treatments for several types of unusual thrombosis were summarized in a review article.

Andexanet Alfa and the Role of Reversal Agents for Factor Xa Inhibitors

By

Caleb Rans, PharmD

Andexanet alfa is the first anticoagulant reversal agent to receive global US FDA approval for patients with life-threatening or uncontrolled bleeding.

A New Genomic Dataset May be a Significant Step Forward in Combating Acute Myeloid Leukemia

By

John Schieszer, MA

A dataset comprising 672 tumor specimens collected from 562 patients describes both genetic and functional information about the biology of AML.

The Role of Viral Infections and Vaccines in the Pathogenesis of Antiphospholipid Syndrome

By

Helen Fosam

Recent evidence links specific bacterial, viral infections, and vaccination to the development of APS, but these associations are not clear-cut.

Eculizumab May Be Safe in Pregnancy, But Data Are Limited

By

Roxanne Nelson, RN, BSN

Eculizumab has been used to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Questions Remain Regarding Venous Thromboembolism Recurrence in Older Adults

By

Roxanne Nelson, RN, BSN

Venous thromboembolism recurrence risk may not be any higher in older patients than in younger patients.

Interferon Alfa Combination Therapy for the Treatment of Myeloproliferative Neoplasms

By

Lauren Dembeck, PhD

Though IFN alfa-2 has been shown to be effective in treating MPNs, it is not the therapy of choice outside of Europe.

More Proactive Approaches May Be Warranted in Older Patients With Sickle Cell Disease

By

John Schieszer, MA

Complications in older patients with sickle cell disease are sometimes misattributed to their disease, possibly delaying appropriate diagnosis and treatment.

Should Infants Be Treated With von Willebrand Factor Concentrate After Complex Cardiac Surgery?

By

Roxanne Nelson, RN, BSN

Researchers comment on the implications of treating newborns and infants with von Willebrand factor (VWF) concentrate.

Managing Medical Complications of Beta-Thalassemia in Adults: An Experience-Based Perspective

By

Lauren Dembeck, PhD

Mortality in beta-thalassemia has decreased due to medical advances, allowing physicians to observe and manage disease-related complications in adult patients.

Improved Reporting of Cardiovascular Events Needed in Chronic Myeloid Leukemia Clinical Trials

By

Roxanne Nelson, RN, BSN

Second- and third-generation tyrosine kinase inhibitors are associated with a variety of cardiovascular events.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

By

Brooke Worster, MD

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

Bryant Furlow

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.